Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM.

Autor: Huemer, Florian1, Melchardt, Thomas1, Jansko, Bettina1, Wahida, Adam2, Jilg, Stefanie2, Jost, Philipp J.2, Klieser, Eckhard3, Steiger, Katja4, Magnes, Teresa1, Pleyer, Lisa1, Greil‐Ressler, Sigrun1, Rass, Christof1, Greil, Richard1, Egle, Alexander1 a.egle@salk.at
Zdroj: European Journal of Haematology. May2019, Vol. 102 Issue 5, p437-441. 5p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje